Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

International team sheds new light on biology underlying schizophrenia

22.07.2014

Genes, pathways identified could inform new approaches to treatment

As part of a multinational, collaborative effort, researchers from Canada's Centre for Addiction and Mental Health (CAMH) have helped identify over 100 locations in the human genome associated with the risk of developing schizophrenia, in what is the largest genomic study published on any psychiatric disorder to date.

The findings, published online in Nature, point to biological mechanisms and pathways that may underlie schizophrenia, and could lead to new approaches to treating the disorder, which has seen little innovation in drug development in more than 60 years.

The research was led by senior author Michael O'Donovan at Cardiff University School of Medicine, and CAMH was the only Canadian site in the collaboration.

Schizophrenia, a debilitating mental illness that affects approximately one out of every 100 people worldwide, is characterized by hallucinations, delusions, and disordered thinking, and often emerges in the teens and early 20s. Its lifetime impact on individuals and society is high, both in terms of direct health-care and other costs, as well as lost productivity and unemployment, which costs an estimated $6.85 billion a year in Canada.

Medications currently on the market treat only one of the symptoms of the illness (psychosis), and there are no effective treatments for the debilitating cognitive symptoms of schizophrenia. In part, treatment options are limited because the biological mechanisms underlying schizophrenia have not been understood.

Recent research focusing on the genetic underpinnings of schizophrenia has revealed the complexity of the illness. Evidence suggests that it is caused by the combined effects of many genes, and roughly two dozen genomic regions have been found to be associated with schizophrenia. The new study confirms those earlier findings, and expands our understanding of the genetic basis of schizophrenia and its underlying biology.

In the genome-wide association study (GWAS) published in Nature, the authors looked at 36,989 genetic samples from schizophrenia patients and 113,075 healthy volunteers and found 108 specific locations in the human genome associated with risk for schizophrenia. Eighty-three of those loci had not previously been linked to the illness.

"Large collaborative efforts such as this one are needed to identify genes that influence complex disorders," said Dr. Jo Knight, Senior Scientist and Joanne Murphy Professor in Behavioural Science, who spearheaded CAMH's involvement in this project. "The result is a major advance in understanding the genetic basis of brain functioning in schizophrenia," said Dr. Knight, who is also Associate Professor of Psychiatry at the University of Toronto.

The study was conducted within CAMH's Campbell Family Mental Health Research Institute, and CAMH researchers Dr. James Kennedy and Dr. Clement Zai were also on the study team.

The study implicates genes expressed in brain tissue, particularly those related to the functioning of brain cells (neurons) and of the channels enabling chemical and electrical signaling between neurons (synapses). These include genes that are active in pathways controlling synaptic plasticity – a function essential to learning and memory – and pathways governing activity in the target cell receiving signals.

Additionally, the researchers found a smaller number of genes associated with schizophrenia that are active in the immune system. This discovery offers some support for a previously hypothesized link between schizophrenia and immunological processes. The study also found an association between the illness and the region of the genome that holds DRD2 – the gene that produces the dopamine receptor targeted by all approved medications for schizophrenia – suggesting that other loci uncovered in the study may point to additional therapeutic targets.

"The fact that we were able to detect genetic risk factors on this massive scale shows that schizophrenia can be tackled by the same approaches that have already transformed our understanding of other diseases," said senior author Dr. Michael O'Donovan, deputy director of the MRC Centre for Neuropsychiatric Genetics and Genomics at Cardiff University School of Medicine. "The wealth of new findings has the potential to kick-start the development of new treatments in schizophrenia, a process which has stalled for the last 60 years."

The study is the result of several years of work by the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC), an international, multi-institutional collaboration founded in 2007 to conduct broad-scale analyses of genetic data for psychiatric disease. A total of 55 datasets from more than 40 different contributors, including CAMH, was needed to conduct the analysis.

The samples used in this study represent all of the genotyped datasets for schizophrenia that the consortium has amassed to date. The PGC is currently genotyping new samples to further study schizophrenia and additional psychiatric diseases, including autism and bipolar disorder.

###

Core funding for the Psychiatric Genomics Consortium comes from the U.S. National Institute of Mental Health (NIMH), along with numerous grants from governmental and charitable organizations, as well as philanthropic donations. The Canadian contribution was funded in part by the Canadian Institutes of Health Research grant MOP-115097.

The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in its field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit http://www.camh.ca.

Media Contact:

Kate Richards
Media Relations
Centre for Addiction and Mental Health (CAMH)
416 535 8501 x36015
kate.richards@camh.ca

Kate Richards | Eurek Alert!

Further reports about: CAMH Genomics Health Medicine Mental Schizophrenia diseases disorder genes illness pathways schizophrenia symptoms

More articles from Life Sciences:

nachricht Cells communicate in a dynamic code
19.02.2018 | California Institute of Technology

nachricht Studying mitosis' structure to understand the inside of cancer cells
19.02.2018 | Biophysical Society

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Contacting the molecular world through graphene nanoribbons

19.02.2018 | Materials Sciences

When Proteins Shake Hands

19.02.2018 | Materials Sciences

Cells communicate in a dynamic code

19.02.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>